ClinicalTrials.gg

Program

VIS-101

A development code. Also written as “ASKG712”, “VIS-101 6.0mg Low concentration” and “VIS-101 6.0mg High concentration”.

Its studies are mostly in Macular Degeneration · Macular Edema, led by 3 companies.

Furthest: phase 2, since Jul 6, 20224 company-led studies, 1 open or runningNext primary completion: Jul 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Visara20 open or runningphase 2since Jul 6, 2022Jul 6, 2022none ahead
AffaMed Therapeutics10 open or runningphase 1since Apr 12, 2022Apr 12, 2022none ahead
Everest Medicines (China)11 open or runningphase 2since Aug 27, 2026Aug 27, 2026Jul 2028phase 2 · NCT07798375

Also a collaborator on its studies: Beijing Aosaikang Pharmaceutical.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 12, 2022First study: phase 1 study in Neovascular Age-related Macular DegenerationNew to AffaMed TherapeuticsAffaMed Therapeutics · NCT05345769 · 21 enrolled · United States
  2. Jul 6, 2022Visara's first study: phase 2 study in Neovascular Age-related Macular DegenerationNew to VisaraVisara · NCT05456828 · 56 enrolled · China
  3. May 11, 2023Phase 1 study in Diabetic Macular EdemaVisara · NCT05940428 · 10 enrolled · China
  4. Aug 27, 2026Everest Medicines (China)'s first study: phase 2 study in Macular DegenerationNew to Everest Medicines (China)Everest Medicines (China) · NCT07798375 · 244 planned

Ahead

  1. Jul 2028Primary completion: phase 2 study in Macular DegenerationEverest Medicines (China) · NCT07798375

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07798375Macular Degeneration2Not yet recruitingEverest Medicines (China)Jul 2028244
NCT05940428Diabetic Macular Edema · China1CompletedVisaraOct 21, 202410
NCT05456828Neovascular Age-related Macular Degeneration · China2CompletedVisaraNov 3, 202556
NCT05345769Neovascular Age-related Macular Degeneration · United States1CompletedAffaMed TherapeuticsNov 4, 202421

How it is read

Names in the registry

  • “ASKG712”, 2 entries
  • “VIS-101 6.0mg Low concentration”, 1 entry
  • “VIS-101 6.0mg High concentration”, 1 entry
  • “VIS-101 9.0mg High concentration”, 1 entry
  • “AM712(ASKG712)”, 1 entry

Codes read as this program: VIS101, ASKG712, AM712.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.